Exelixis Inc
(NAS:EXEL)
$
36.115
0.265 (0.74%)
Market Cap: 10.31 Bil
Enterprise Value: 9.21 Bil
PE Ratio: 23.15
PB Ratio: 4.54
GF Score: 91/100 Exelixis Inc at RBC Global Healthcare Conference Transcript
May 19, 2020 / 06:30PM GMT
Release Date Price:
$24.88
(-3.15%)
Kennen B. MacKay
RBC Capital Markets, Research Division - MD & Co-Head of US Biotechnology Research
Hi. My name is Kennen MacKay. I'm one of the senior biotechnology analysts here at RBC, and it's my great pleasure to kick off this next session with Exelixis. And from Exelixis. I'm joined by Dr. Mike Morrissey, the President and Chief Executive Officer.
Mike, thanks so much for joining this afternoon.
Michael M. Morrissey
Exelixis, Inc. - CEO, President & Director
How you're doing today? Glad to be on the call with you virtually, not the same as being in New York, but not bad either. So hope you're doing good.
Questions & Answers
Kennen B. MacKay
RBC Capital Markets, Research Division - MD & Co-Head of US Biotechnology Research
Thanks, Mike. Likewise. So maybe it seems like Exelixis is really firing on all cylinders now, both commercially and clinically with some really very impressive data sets out recently. And I'd love to get to those. But first, cabo really surprised to the
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot